BRIEF-Concordia International confirms strategic review is ongoing

Wed Aug 3, 2016 9:44am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Aug 3 (Reuters) - Concordia International Corp :

* Concordia International Corp. Confirms that strategic review is ongoing and provides update on its business

* Confirmed that its review of strategic alternatives is ongoing and provided an update on its business

* Concordia has no liquidity or debt issues

* There was one formulary change affecting two products in its North America portfolio

* CVS did not reimburse for nilandron at all in past three years and has reimbursed dutoprol twice in 2016

* Concordia International Corp. Confirms that strategic review is ongoing and provides update on its business

* CVS Health confirmed that nilandron and dutoprol will be removed from CVS Health's formulary

* Removal of treatments from cvs health's formulary is immaterial to business Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)